Accessibility StatementSkip Navigation Following peer-reviewed publication and independent expert review of findings, the LOI advances Lunai's tumor-regressing immune-cell platform toward scalable therapies for aggressive cancers SACRAMENTO, Calif., Nov. 25, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved complete regressi ...